Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma is a phase 2, interventional study registered as NCT06484153 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 25 participants, started 2024-07-22 and due to reach its primary completion in 2026-07-22. Interventions recorded: Pirfenidone; Fruquintinib; Pembrolizumab. Conditions listed: To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma; To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer; Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer. Primary outcome: Progression Free Survival (PFS); Occurrence of Grade 4 toxicity; Occurrence of Grade 3 toxicity. Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of unresectable locally advanced, recurrent or metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.